A drug that boosts bone growth in children with achondroplasia — the most common form of dwarfism — may also reduce their chances of SIDS, sleep apnoea and needing surgery.
How quickly and effectively can you deliver breakthrough, high-quality new therapies to market?
US scientists have developed an ingestible device that can safely monitor vital signs like breathing and heart rate from inside of us.
mRNA vaccines and therapies will soon be produced for clinical trials in a dedicated laboratory at The University of Queensland (UQ).
With Australia officially in its eight wave of COVID-19, the time is ripe to look back at the challenges faced and lessons learnt from vaccine development during the early days of the pandemic.
The intravenous needle remains soft once it has been used, preventing accidental needlestick injuries and unethical reuse.
The invention takes a comprehensive 'all in one' approach to wound healing, accelerating the process on several fronts.
Researchers conducted a randomised, double-blind, placebo-controlled trial of 97 people to investigate methotrexate, a low-cost treatment for inflammatory joint conditions.
A new approach to healing muscle injury employs an injectable tissue prosthesis in the form of conductive hydrogels combined with a robot-assisted rehabilitation system.
Scientists have found success in treating an arguably neglected inflammatory condition, polymyalgia rheumatica, with a drug that could provide an alternative to steroids for patients.
Medtech company Bactiguard has developed a thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices.
Atmo Biosciences has created a gas-sensing capsule the size of a vitamin pill which, when swallowed, can electronically report data about the human gastrointestinal system.
Called Airbender, the wearable upper limb prosthetic is designed to be affordable, comfortable and intuitive for young users.
The drug known as PXS‐5505 returns the tumour microenvironment to a more 'normal' state by reducing fibrosis and decreasing tumour stiffness.
The oral drug muvalaplin is claimed to provide world-first treatment for lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack and stroke.